^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

minocycline

Associations
Company:
Generic mfg.
Drug class:
Immunomodulator, Protein synthesis inhibitor, IL-1α inhibitor, IL-6 modulator
Related drugs:
Associations
3d
Fecal Molecular Susceptibility-guided Hp First-line Therapy (clinicaltrials.gov)
P4, N=544, Not yet recruiting, Shanghai Zhongshan Hospital
New P4 trial • HEOR
|
minocycline
3d
Fecal Molecular Susceptibility-guided Hp Rescue Therapy (clinicaltrials.gov)
P4, N=290, Not yet recruiting, Shanghai Zhongshan Hospital
New P4 trial • HEOR
|
minocycline
7d
Microglia alter autonomic nuclei neuronal activation after peripheral cytokine challenge. (PubMed, Am J Physiol Cell Physiol)
When animals were challenged with TNFα after receiving minocycline, fewer c-Fos-positive cells were induced in the DVC and selectively in the rostral VLM. These findings highlight the spatial selectivity of cells in the brainstem to increased peripheral pro-inflammatory signaling, as well as the impact of resident microglia on autonomic circuitry responses.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
|
minocycline
11d
Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation. (PubMed, JCI Insight)
Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRAS-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in bAVM patients.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
|
KRAS mutation • KRAS G12
|
minocycline
16d
New trial
|
minocycline
16d
Effect analysis and mechanism study of Abrocitinib in the treatment of bullous pemphigoid (ChiCTR2500114958)
P=N/A, N=30, Completed, Peking University First Hospital; Peking University First Hospital
New trial
|
minocycline
16d
Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage: a multicenter, randomized, open-label, blinded endpoint clinical study (ChiCTR2500114607)
P=N/A, N=1248, Not yet recruiting, The First Hospital of Jilin University; The First Hospital of Jilin University
New trial
|
minocycline
16d
Efficacy and Safety of Minocycline in Patients with Acute Spontaneous Intracerebral Hemorrhage (ChiCTR2600117240)
P4, N=1192, Not yet recruiting, Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University
New P4 trial
|
minocycline
16d
New P4 trial
|
minocycline
16d
Enrollment open
|
minocycline
26d
Minocycline alleviates mechanical allodynia and modulates hippocampal neuroinflammatory markers in a rat model of neuropathic pain induced by spinal nerve transection. (PubMed, Neuroreport)
Minocycline administration significantly mitigates mechanical allodynia and modulates hippocampal neuroinflammatory markers in a rat model of neuropathic pain. These results highlight minocycline's potential as a therapeutic option for neuropathic pain, particularly in targeting neuroinflammation within the hippocampus.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • BDNF (Brain Derived Neurotrophic Factor)
|
minocycline